Results of Studies on the Effect of Feprazone on Lumbago by the Group Comparison Method
スポンサーリンク
概要
- 論文の詳細を見る
The clinical usefulness of feprazone on lumbago was examined by the group comparison method, a double-blind controlled study dosing feprazone (300mg/day) and ibuprofen (600mg/day).<BR>As results, feprazone (300mg/day) showed the same extent of relief on lumbago as that of ibuprofen (600mg/day), which has already been recognized as a highly useful drug to control lumbago.<BR>In feprazone, as for safety, side effects, especially gastro-intestinal disorders, were slightly less than ibuprofen. Thus feprazone was concluded to be a commendable drug for the treatments of lumbago.
著者
関連論文
- 110. 変形性股関節症に対する三層カップ形成術々後PTの経過
- 変形性関節症に対するTS-110の臨床評価 : ジクロフェナクナトリウムを対照薬とした多施設二重盲検比較試験
- 抗炎症鎮痛剤アルクロフェナックの腰痛性疾患に対する薬効検定 : 二重盲検法による
- 腰痛症の診断と治療
- トルフェナム酸(GEA)の抜歯後疼痛に対する臨床評価-2-二重盲検法による多施設協同研究
- Clinical Study of the Intra-articular Injection of Arteparon for Osteoarthritis of the Knee Joint:Double Blind Controlled Study
- Results of Studies on the Effect of Feprazone on Lumbago by the Group Comparison Method
- The Absorption and Excretion of Protizinic Acid:Blood Concentration, Urine Concentration and Milk Concentration in Human
- The Biological Fate of Suxibuzone V:Plasma Levels and Urinary Excretion in Man after Single Oral Dose of Suxibuzone and Comparison with Phenylbutazone
- タイトル無し
- Phase I study of N-(2-mercapto-2-methylpropionyl)-L-cysteine (SA96). II. Continuous 6-day administration study.
- N-(Meercapto-2-methylpropionyl)-L-Cystein(SA96) の臨床第一相試験 (第一報) 単回投与試験